BioCrine AB
Biocrine is an R&D company focused on discovery and preclinical development of approaches to prevent and treat diabetes and its complications. The organization develops and commercializes programs originating from academic research and operates a longitudinal intravital imaging platform based on transplantation of cells into the anterior chamber of the eye for single‑cell resolution studies. Research activities include target discovery and validation, preclinical transplantation models, biomaterials for islet culture and vascularization, stem cell‑derived islet maturation, and development of molecular therapeutics and implantable micro‑optical sensors.
Industries
Nr. of Employees
small (1-50)
BioCrine AB
Patents
Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
US-10695425-B2
View Details
Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
US-10695425-B2
View DetailsProducts
Preclinical program: apolipoprotein CIII modulation
Preclinical development program focused on lowering apolipoprotein CIII to reduce beta‑cell toxicity and metabolic derangements using oligonucleotide and antibody approaches.
Preclinical program: isoform‑selective modulation of insulin receptor signaling
Screening and assay platform to identify compounds that selectively modulate signaling through different insulin receptor isoforms for cell‑type selective effects on insulin signaling.
Preclinical program: modulation of calcium channel β‑subunit
Program targeting calcium channel β‑subunits in beta cells to enhance glucose‑dependent insulin secretion and support beta‑cell survival; includes preclinical evaluation.
Preclinical program: modulation of inositol pyrophosphate metabolism (IP7/IP6K1/DIPP)
Program to modulate intracellular inositol pyrophosphate levels in beta cells by targeting IP6K1 or DIPP to increase the readily releasable pool of insulin granules and improve first‑phase insulin release.
Insulin receptor
A screening platform developed by Biocrine that allows the identification of whether substances like peptides or aptamers positively or negatively affect insulin signaling via insulin receptor A (IR-A) or insulin receptor B (IR-B) using fluorescence detection.
Insulin receptor isoforms
Research program targeting insulin receptor isoforms for therapeutic development.
Preclinical program: apolipoprotein CIII modulation
Preclinical development program focused on lowering apolipoprotein CIII to reduce beta‑cell toxicity and metabolic derangements using oligonucleotide and antibody approaches.
Preclinical program: isoform‑selective modulation of insulin receptor signaling
Screening and assay platform to identify compounds that selectively modulate signaling through different insulin receptor isoforms for cell‑type selective effects on insulin signaling.
Preclinical program: modulation of calcium channel β‑subunit
Program targeting calcium channel β‑subunits in beta cells to enhance glucose‑dependent insulin secretion and support beta‑cell survival; includes preclinical evaluation.
Preclinical program: modulation of inositol pyrophosphate metabolism (IP7/IP6K1/DIPP)
Program to modulate intracellular inositol pyrophosphate levels in beta cells by targeting IP6K1 or DIPP to increase the readily releasable pool of insulin granules and improve first‑phase insulin release.
Insulin receptor
A screening platform developed by Biocrine that allows the identification of whether substances like peptides or aptamers positively or negatively affect insulin signaling via insulin receptor A (IR-A) or insulin receptor B (IR-B) using fluorescence detection.
Insulin receptor isoforms
Research program targeting insulin receptor isoforms for therapeutic development.
Services
Provision of anterior‑chamber transplantation and longitudinal intravital imaging to external academic and industry research projects on a project basis.
Provision of anterior‑chamber transplantation and longitudinal intravital imaging to external academic and industry research projects on a project basis.
Expertise Areas
- Intravital longitudinal single‑cell imaging
- Diabetes target discovery and preclinical validation
- Islet biology and beta‑cell physiology
- Preclinical transplantation and disease modeling (rodent and non‑human primate)
Key Technologies
- Anterior‑chamber cell transplantation for intravital imaging
- Longitudinal single‑cell intravital microscopy
- Microendoscopic and microscale imaging systems
- Fluorescent reporter assays for Ca2+ dynamics and insulin exocytosis
News & Updates
Announcement of an ERC Proof of Concept grant awarded to advance anterior‑chamber intravital imaging methodology.
Summary of a publication reporting targeted RNA approaches to prepare pancreatic islet cells for transplantation (reported in Signal Transduction and Targeted Therapy).
A comprehensive set of peer‑reviewed publications documents development and application of anterior‑chamber transplantation, intravital imaging methods, islet physiology, biomaterials for islet culture, and translational preclinical studies including non‑human primates.
Announcement of an ERC Proof of Concept grant awarded to advance anterior‑chamber intravital imaging methodology.
Summary of a publication reporting targeted RNA approaches to prepare pancreatic islet cells for transplantation (reported in Signal Transduction and Targeted Therapy).
A comprehensive set of peer‑reviewed publications documents development and application of anterior‑chamber transplantation, intravital imaging methods, islet physiology, biomaterials for islet culture, and translational preclinical studies including non‑human primates.